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Abstract
Background: The most common male malignancy in the United States is prostate cancer; however its rate of
occurrence varies significantly among ethnic groups. In a previous cDNA microarray study on CaP tumors from African
American (AA) and Caucasian (CA) patients, we identified 97 candidate genes that exhibited opposite gene expression
polarity with respect to race groups; genes up-regulated in AA were simultaneously down-regulated in CA.
Purpose: The purpose of this study was to narrow the 97 member gene list, to a smaller number of genes in order to
focus studies on a limited number of genes/SNPs that might explain prostate cancer disparity in African Americans.
Methods: We performed genotype-phenotype, SNP and expression transcript levels correlations using HapMap
Yoruba population with 85 of our 97 prostate candidate genes using SCAN database.
Results: Findings revealed an association of SNPs surrounding ABCD3 gene with basal gene expression of
RanGAP1 is important in prostate tumors in AA. Hence, to confirm our results in clinical biospecimen, we
monitored expression of ABCD3 in a novel panel of African American and Caucasian prostate cancer paired cell
lines. The LNCaP, C4-2B showed 2-fold increase; MDA-2PC-2B cell line, derived from AA, showed highest fold-
change, 10-fold. The EGFR over expressing DU-145 WT cell line exhibited a 4-fold increase in expression relative to
non transfected DU-145 prostate cell lines. Furthermore, Ingenuity Network analysis implicated our AA prostate
candidate genes are involved in three network hubs, ERK, MapK and NFkB pathways.
Conclusions: Taken together, these findings are intriguing because other members of the ABC gene family, namely,
ABCC3, ABCD1, and ABCD2 have been shown to confer chemoresistance in certain cancer types. Equally important, is
the fact that activation of the MapK/ERK pathway via EGFR stimulation is vital for increased transcription of numerous
cancer related genes. It is especially noteworthy that overexpression of EGFR has been widely observed in AA prostate
tumors. Collectively our findings lead us to think that a novel signaling cascade, through which increased
aggressiveness and chemoresistance is achieved, may explain prostate cancer health disparity in AA males and the
nature of aggressive CaP tumors in general.
Introduction
Prostate cancer (CaP) is the second leading cause of
cancer-related death among all men in the United States.
However, incidence and mortality rates for this disease
vary substantially among geographic areas and ethnic
groups. Most notably African American men (AA) in the
United States have the highest risk (19%) of developing
prostate cancer, and due to the development of more
aggressive disease, they have more than twice the mortality
rate observed for other racial and ethnic groups [1]. The
explanation for these differences is still unknown; however
proposed explanations include genetic factors, dietary fac-
tors, behavioral factors, biological tumor aggressiveness,
socio-economic factors and gene-environment interaction
[2-35]. While AA race/ethnicity is one of the three pri-
mary non-modifiable risk factors confirmed for CaP, there
are only a few published cDNA microarray studies [36-38]
that have focused on gene expression differences in AA
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prostate cancer health disparity. Previously we identified
97 genes differentially expressed in AA prostate tumors.
To narrow down this number of genes, we utilized
advance bioinformatics methods. In the present study we
performed genotype-phenotype or SNP and expression
transcript level correlations of HapMap lymphoblastoid
cell lines from Yoruba population to the 97 prostate candi-
date genes in AA, in an attempt to ferret out genetic
variants associated with AA population. In addition, we
used Ingenuity pathway analysis to calculate the probabil-
ity of finding our set of candidate genes within a given
pathway(s) to establish probable signal transduction
mechanisms.
Methods
Microarray prostate candidate gene list for AA tumors
T h eg e n el i s tu s e di nt h i ss t u d yw a so b t a i n e df r o mo u r
previously published cDNA microarray study [36].
SCAN database analysis to look for gene-gene
interactions
SCAN is a large-scale database of genetics and genomics
data associated to a web-interface and a set of methods
and algorithms that can be used for mining the data in it
(http://www.scandb.org/newinterface/about.html). Infor-
mation on the relationship between SNPs and expression
transcript levels (eQTLs) that is served by SCAN comes
from a series of publications describing studies character-
izing eQTLs in lymphoblastoid cell lines from HapMaP
Caucasian (CEU) and Yoruba (YRI) samples for which
transcript levels have been assayed using the Affymetrix
Human Exon 1.0 ST Array [39-44].
The SCAN database contains two categories of SNP
annotations: (1) Physical-based annotation or SNPs cate-
gorized according to their position relative to genes (intro-
nic, antigenic, etc.) and according to linkage disequilibrium
(LD) patterns (an intergenic SNP can be annotated to a
gene if it is in LD with variation in the gene). (2) Functional
annotation where SNPs are classified according to their
effects on expression levels, i.e. whether they are eQTLs for
that gene. Information on physical, functional and LD
annotation served on the SCAN database comes directly
from public resources, including HapMap (release 23a),
NCBI (dbSNP 129), or is information created by using data
downloaded from these public resources. In SCAN data-
base, genotype data for the YRI samples was obtained from
HapMap project (http://www.hapmap.org). Genotype and
gene annotations were obtained from NCBI, dbSNP 129.
We uploaded appropriate gene identifiers for our pros-
tate candidate genes and queried for SNPs that are signif-
icantly associated with expression of prostate candidate
genes in Yoruba (YRI) population in lymphoblastoid cell
lines. SCAN genetic and genomic data for the Yoruba
Population in Ibaden, Nigeria, Africa was used because of
close ancestral ties of Nigerians to African Americans.
The SCAN analysis output reports a list of SNPs in gene
(s) that predict expression quantitative trait loci found in
mRNA profiles from YRI with p-values less than 0.0001.
Hugo gene symbols
To enter a list of genes into SCAN, it is first necessary to
use the HUGO (Human Genome Organization) gene sym-
bol - the unique gene name and symbol given to each
human gene by The HUGO Gene Nomenclature Commit-
tee (HGNC). From our 97 gene list, we were able to obtain
HUGO gene symbols for 85 of the 97 genes (hereafter
referred to as 85/97).
Ingenuity pathway analysis
Ingenuity software (http://www.ingenuity.com/) was used
for pathway analysis. Ingenuity software calculates p-value
for the probability of finding a set of genes within a given
pathway. Fisher’s exact test was used to calculate the
p-values associated with finding 536 prostate genes
obtained during this study (which includes 85/97 candi-
date genes, from previous differential expression study
[36] and 451 candidate genes that are corresponding to
Cis- regulatory SNPs, that are significantly associated with
the 85 candidate genes) within a annotated network from
Ingenuity Knowledge Base.
RT-PCR validation in novel panel of prostate cancer lines
RT-PCR assay was done using a 7500 FAST Real-Time
ABI System.
Briefly, total RNA from each cultured prostate cell line
was extracted, separately, with RNAzol B (Tel-Test Inc.,
Friedswood, Tx) according to the manufacturer’s protocol
and quantified with Nucleic Acid Quantitation Kit (NBI,
Plymouth, MN). Total RNA (1 ug) was reverse transcribed
into cDNA with RT
2 F i r s ts t r a n dK i t( S A B i o s c i e n c e s / A
Qiagen Company)) and 1.10 of the reverse-transcribed
product from each sample was used for PCR to amplify
ABCD3 gene, using a RT
2 qPCR Primer Assay for Human
ABCD3 (SABiosciences/A Qiagen Company) The expres-
sion of GAPDH was used as an internal control/house-
keeping gene. Experimental conditions for the ABCD3
gene was optimized to analyze the amplified product in
the linear range of amplification by adjusting amplification
cycles for each set of primers. The expected band size (bp)
size of the PCR product was 83, as described by vendor
(SABiosciences).
Novel prostate cancer cell lines: description
Non-malignant (RC-77N/E) and malignant (RC-77T/E)
prostate cells were derived from an African American
prostate cancer patient and both are androgen sensitive
[45]. RC-77N/E cells were isolated from pathological
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T3 tumor. Both cell lines are cultured in Keratinocyte
Serum-Free Medium (KGM) Life Technologies,
Gaithersburg, Md., USA), supplemented with bovine
pituitary extract (BPE), recombinant epidermal growth
factor (rEGF), 1% (v/v) penicillin-streptomycin-neomy-
cin (PSN) antibiotic mixtures and 1% (v/v) amphotericin
B (KGM) (Life Technologies, Gaithersburg, MD, USA).
MDA-2PC-2B, also derived from an African American
patient are androgen dependent, metastatic and are cul-
tured in F12 K medium. DU-145, a cell line originally
derived from a brain metastasis of a human prostate
adenocarcinoma [46] retains the androgen independence
of the original tumor and does not express a functional
AR [47]. This cell line has both LHRH-R and epidermal
growth factor receptors (EGFR) and produces the EGFR
ligands, transforming growth factor a (TGF-a) and EGF
[48,49]. Utilizing established protocols, DU-145 cells
were transfected by retroviral-containing EGFR con-
structs [50]. The wild-type (WT) EGFR construct is a
full-length cDNA derived from a placental cDNA
library. Cells expressing WT EGFR at levels that escape
downregulation demonstrate enhanced invasiveness in
vitro [51]. LNCaP cells were derived from a lymph node
metastasis [52]. The Caucasian LNCaP, C42-B prostate
cancer cell lines were maintained in T-medium as pre-
viously described.
Results
Origin of the 97 prostate candidate genes
To detect for gene-gene interactions in AA prostate
tumors in African American males, we used a cDNA
microarray gene list obtained from a pilot project cDNA
microarray comparison study of prostate tumor gene
expression in AA and CA [36]. To obtain differentially
expressed gene or the gene list, we used four snap frozen
tumors and four snap frozen non-tumor matched controls,
each, from AA and CA . All tumors had a Gleason score
of six. Gene expression profiles were measured for each of
the micro dissected CaP tumor samples using Affymetrix
U133A human arrays as described in [36]. Each of the 8
prostate tumors and 8 matched controls underwent single
hybridization and was arrayed individually (i.e. samples
were not pooled). Data from the micro array CEL files
were uploaded to R-Bioconductor for analysis [53]. We
paired normal AA tissue to tumor AA and paired normal
CA to tumor CA to generate for case paired t-tests for
each race group; gene lists of differentially expressed genes
in AA Tumor vs. AA controls and of CA Tumor vs. CA
controls were generated. We looked for differentially
expressed genes that met the filtering criteria of a 4.0-fold
change and a p< 0.0001. Neither the comparison of AA
tumor to AA controls nor the comparison CA tumors to
CA controls yielded genes that met both parts of our
filtering criteria. However, when we looked at the ratio of
CA tumor/CA normal to AA tumor/AA normal (case-
m a t c h e dr a t i o s - r a c eg r o u pt ests for specific expression
trends) we found 97 statistically significant, differentially
expressed genes with 4-fold or greater fold change and
p<0.0001. It was necessary to ratio the ratios to control for
the high degree of genetic variation in AA tumor and AA
non-tumor samples.
Scan database SNP and expression transcript level
association results
After uploading our 85/97 prostate candidate genes with
appropriate HUGO gene symbols and querying for SNPs
in our 85/97 significantly associated with SNPs in the
HapMap Yoruba (YRI) population; approximately, 26527
genotype-phenotype associations were obtained with a
p-value < 10
-3, of which 17542/26527 associations had a
p-value <10
-4 ( data not shown)
SNPs and expression transcript levels (eQTL) associa-
tions results identified two gene-gene associations. Asso-
ciation results in lymphoblastoid cell lines showed that
expression of RanGAP1 gene which is a key regulator of
the RAN GTP/GDP cycle, located on chromosome 22,
may be involved with several SNPs in ABCD3 gene which
is ATP-Binding cassette, subfamily member that is located
on chromosome 1 (Shown as encircled dots on far left in
Figure 1). In addition, expression of STXBP2 gene which
is a syntaxin-binding protein that is located on chromo-
some 19 may be involved with a region on chromosome
12. The chromosome 12 region consists of transmem-
brane and tetratricopeptide repeat containing 2 (TMTC2)
gene that is approximately 400kb away from the region
where STXBP2 gene is associated (shown as encircled
dots on far right of Figure 1). Genome-wide results also
showed that there were 1167 cis interactions (where
expression gene and SNP are located on the same chro-
mosome) out of 26527 associations with a p-value < 10
-3.
Most of the cis-regulatory associations were found in pro-
tein coding regions.
CaP candidate genes found in ERK, MapK, NFKB pathways
Pathway analysis was performed in an attempt to define
biological relationships among candidate genes identified
during our study using the genes that are involved with
the downstream effects of SNPs along with the 85/97
candidate prostate cancer genes as described in meth-
ods. Ingenuity Pathway Analysis (IPA) was used to per-
form the pathway analysis. This software consists of a
curated database and several analysis tools to determine
the probability of finding a set of genes within annotated
pathway or network annotation. Results showed a high
probability for finding our candidate genes in three net-
work hubs centered on ERK, MAPK and NFkB path-
ways (Shown in Figures 2, 3 and 4, respectively). These
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Figure 1 GWAS Plot of Gene-Gene Associations illustrates p-values (shown on y-axis) of SNP for gene variants found on chromosomes 1-22(x-
axis). The x-axis shows Chromosomes 1 thru 22. Each dot represents gene variants or SNPs. In the circled dots to the extreme left positioned
above Chromosome 1 (x-axis), the dot with the highest p-value represents an ABCD3 gene variant with a defined rs# that is strongly interacting
with RANGAP1 to influence CaP tumors in African American. All of the dots in the circle reveal an association of SNPs surrounding ABCD3 gene
with basal gene expression of RanGAP1. This variation in gene expression RanGAP1 might be influenced by the SNPs in ABCD3 Similarly in the
circled points to the far right, positioned above chromosome 12 ( x-axis), the dot with the highest p-value represents the TMTC2 gene variant
with a defined rs#, that strongly interacts with STXBP2. All the dots in the circle represent an association of SNPs surrounding TMTC2 gene with
basal gene expression of STXBP2.
Figure 2 Ingenuity Pathway Analysis identified ERK as the Top network signaling Hub where the shaded shapes indicate the candidate genes
from the present study. RANGAP1 is found in the ERK pathway. Dotted line indicates an indirect cellular interaction and solid lines indicate a
physical interaction between genes. Genes are identified with their HUGO symbol. Dotted line indicates an indirect cellular interaction and solid
lines indicate a physical interaction (acts on or inhibits) between genes. Different shapes (diamond, circle or rectangles) of the nodes represent
functional classification of the genes.
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Fisher’s exact test were associated with genetic disorder,
cellular development, cell death and cell signaling.
Direct interactions between the genes in the network
pathways are indicated by solid lines and indirect rela-
tionships are indicated by dashed lines. The shaded
genes represent our 536 candidate genes identified in
our association study as described in method section (85
candidate genes + 451 cis-regulatory genes that are
associated with the 85 candidate genes). Diamond
shapes represent enzymes, oval represent transcription
regulators. Squares: cytokines and triangles: kinases. (For
full explanation of shapes and the functional classifica-
tion they represent go to http://www.springerimages.
com/Images/LifeSciences/1-10.1007_s12014-010-
9053-0-2),
ABCD3 gene highly expressed in aa metastatic prostate
cancer lines
Our association study of 85 candidate genes with gen-
ome-wide SNPs in HapMap YRI lymphoblastoid cell
lines has revealed an association of SNPs surrounding
ABCD3 gene with basal gene expression of RanGAP1
using data obtained from SCAN database (Figure 1). This
variation in expression levels of RanGAP1 might be influ-
enced by the SNPs in ABCD3. To confirm our results
obtained during the association study, we tested ABCD3
expression in clinically relevant cell lines. Verification of
Figure 3 Ingenuity Pathway Analysis identified MapK as second Top network signaling Hub where the shaded shapes indicate the candidate
genes from current study. Dotted line indicates an indirect cellular interaction and solid lines indicate a physical interaction between genes.
Molecules are identified with their HUGO symbol. Different shapes (diamond, circle or rectangles) of the nodes represent functional classification
of the genes shown.
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revealed an increase in expression with increased metas-
tasis across a novel panel of African American and Cau-
casian prostate cancer paired cell lines (Figure 5). The
malignant RC-77T/E cells isolated from AA showed 2-
fold increased expression compared to non-malignant
RC-77N/E matched pair (Figure 5). The metastatic,
androgen dependent MDA-2PC-2B cell line derived
from AA ) exhibited a 10-fold ABCD3 expression (Figure
5 ) .P r e v i o u s l yw eh a v ed e m o n s t r a t e dt h a tD U - 1 4 5W T
(EGFR overexpressing) cells exhibit increased invasive-
ness and metastasis both in vitro and in vivo [49]. There-
fore, we examined ABCD3 gene expression in the
DU-145 WT cell and in non-transfected DU-145 cells.
DU-145 WT cells showed a 4-fold increase in expression
relative to DU-145 prostate cell lines (Figure 5). A similar
pattern of expression was observed in the androgen inde-
pendent metastatic C4-2B cells derived from Caucasian
androgen dependent LNCaP cells, thus providing firm
evidence of increased ABCD3 gene expression with
increased prostate cancer progression in AA tumors
(Figure 5).
Discussion/conclusion
To address the underlying genetic cause of prostate cancer
burden in African Americans, we previously obtained a
cohort of normal tumor paired samples from African
American and Caucasian men, and looked for differential
gene expression within each group. Utilizing a strict filter-
ing criteria, we observed over 97 differentially expressed
genes in our African American vs. Caucasian sample set
[36]. To further narrow the list to genes of utmost impor-
tance in prostate disease onset, we used a genome-wide
association approach that allowed us to rapidly scan for
SNPs in the genome of healthy Yorubai population (Yoru-
bai from Ibaden, Nigeria) that might possibly be associated
Figure 4 Ingenuity Pathway Analysis identified NFKB as the Top Network signaling Hub where the shaded shapes indicate the candidate genes
from the present study. Dotted line indicates an indirect cellular interaction and solid lines indicate a physical interaction (.I.e. binding) between
genes. Molecules are identified with their HUGO symbol. Different shapes (diamond, circle or rectangles) of the nodes represent functional
classification of the genes shown.
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HapMap database of YBI, Nigerian lymphoblastoid cell
lines, since there are a limited number of SNP databases
containing African American patients. Most importantly
the Yorubai population rather than the Caucasian (CEU)
population was utilized because the close ancestral ties
[54] between West African Africans and African Ameri-
cans would increase our chances of finding similar genetic
variants associated with prostate disease in men of African
descent (Nigerians and African Americans). Approxi-
mately 536 genes were identified in our association study
as described in methods section (85 candidate genes + 451
cis-regulatory genes) that are associated with the 85/97
candidate genes. Herein we report that a significant num-
ber of direct gene-gene interactions were found, however
the most significant interactions were observed on chro-
mosome 1 and chromosome 12. Given the importance of
these chromosomes in prostate disease, it was appropriate
to investigate ABCD3 gene involvement in African Ameri-
can prostate cancer. Our analysis of gene-gene interactions
on chromosome 1 and 12 revealed that ABCD3/RanGAP1
and STXBP and TMTC2 gene showed the strongest asso-
ciations. Of these the ABCD3/RanGAP1 genes were pre-
dicted to have the most significant interactions. As such
neither ABCD3 or RanGAP1 expression has been impli-
cated in prostate cancer, there f o r ew ec h o s et of o c u so n
ABCD3. The ATP-binding cassette genes consist of var-
ious subfamilies, are typically expressed in both normal
and cancer cells. Their functions have been implicated in
acquired Multidrug Resistance, MDR, in cancer cell lines.
For example, recent reports have shown that MCF-7/
AdVp3000 cells that were derived by selection for growth
in the presence of doxorubicin, exhibit a 459-fold overex-
pression of ABCC3 relative to the parental cell line [55].
A similar situation in prostate cancer cell lines has been
observed as MDR1/Pgp/ABCB1 and multidrug resistance-
associated protein-1(MRP1/ABCC1), with the half ABC
transporter, breast cancer resistance protein BCRP/
ABCG2, is able to selectively isolate the putative prostate
stem cells from the prostate tissue microenvironment
through constitutive efflux of androgen and protects the
putative tumor stem cells from androgen deprivation,
hypoxia, or adjuvant chemotherapy [56]. These findings
are supported by unpublished data, from Yates laboratory,
that suggest that fluorescence-activated cell sorting, FACS
isolation of the (SP) cells, selective for functional ABC
transporter pumps, have higher in vivo tumorigenicity
compared to other cell surface markers (unpublished
data). Thus, it is possible that ABCD3 could possibly con-
tribute to aggressive prostate cancer.
Multiple ABC family genes have been implicated to play
a role in chemoresistance and progression of prostate and
breast cancer, however given the large number of family
subtypes only a few have been associated with prostate
cancer progression to aggressive disease. Since ABCD3
gene expression has not been identified previously in pros-
tate cancer, we verified this in commonly utilized prostate
cancer cell lines, as well as in a normal and primary tumor
cell line pair derived from an African American prostate
cancer patient [45,57]. As in prostate patient samples,
ABCD3 was consistently overexpressed in the RC-77N/E/
RC-77T/E, LNCaP/C4-2B models, with MDA-PC-2B cells
exhibiting the highest expression (10-fold). This data is
consistent with the expression of other members of the
ABC gene family that have been implicated in prostate
cancer, and serves as proof-of-principle evidence that
ABCD3 overexpression is indeed correlated with prostate
cancer progression. That MDA-2PC-2B cells exhibited the
highest expression levels, further implicates a role for
ABCD3 in African American prostate cancers.
To further substantiate the link of ABCD3 with other
cell signaling molecules that contribute to prostate can-
cer, we utilized an indirect in silico ingenuity pathway
analysis. ABCD3, showed a high probability of being
found within three growth factor initiated network hubs
involving ERK, MAPK and NFkB proteins. The ERK
MAPK has been implicated in a number of pathophysio-
logical events including androgen receptor signaling [58]
and the epithelial-to-mesenchymal (EMT) [59] that
occurs as cancer cells acquire the property to metastasize.
That we observed a 4 fold increase in ABCD3 expression
in an EGFR overexpressing DU-145 WT cell line com-
pared to non-transfected DU-145 cells, highlights a puta-
tive novel regulator of ABCD3. EGFR is overexpressed in
Figure 5 Expression of ABCD3 in panel of paired prostate cancer
cell lines. (A) qRT-PCR of non-malignant African American RC-77N/E
was compared to malignant RC-77T/E cells, DU-145 was compared
to DU-145 WT (EGFR overexpressing), LnCaP was compared to C4-
2B, and all samples were compared to African American MDA-PC-2b
cells. Results shown is representative of experiments performed in
triplicate.
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activator of MAPK ERK in normal and cancer cell [61].
Furthermore overexpression is sufficient to increase
proliferation, invasion related EMT, and metastasis
[49,62,63]. Thus, it appears that ABDC3 is a novel pros-
tate cancer associated gene, that could, in part, be regu-
lated by EGFR signaling.
Although further studies to investigate the ABCD3/Ran-
GAP1 relationship need to be conducted, our results
clearly illustrate the utility of high density SNP analysis, in
conjunction with appropriate cell lines that represent the
clinical conditions, to identify regulatory genes in prostate
cancer. Although a more in-depth analysis of the exact
role of ABCD3 in such events as cell proliferation, and
chemoresistance is warranted and are underway. The
results of this study provide a rationale for use of DU-145/
DU-145WT and MDA-PC-2B as culture models to study
molecular mechanisms associated with the health disparity
in African American prostate cancer patients.
Limitation of study
The 97 member candidate gene list was derived from a
limited number of prostate tumor samples and matched
control from AA and CA. Nonetheless, approximately,
26527 genotype-phenotype associations were obtained
with a p-value < 10
-3, of which 17542/26527 associations
has a p-value <10
-4. The associations with the highest P-
values showed two distinct association; one of which has
led us to think that the ABC gene family plays an
important role in prostate cancer aggressiveness and
chemoresistance.
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